In our first podcast interview of 2023, BioPharma Reporter spoke with Dr Sarah Bateup, therapy lead at Clerkenwell Health, about the potential of psychedelic medicine and her work within the psychedelic therapy training space.
Dr. Bertalan Mesko discusses the role of artificial intelligence in the future of health care, how patients are driving adoption – and the seemingly thin line between “healing” and “upgrading.”
Changing pills to a more user-friendly formulation can increase patient compliance, brand loyalty, and extend IP exclusivity, says CMO Hermes in an exclusive podcast.
In the war against counterfeits, regulators have concentrated on serialisation and ePedigree and missed an opportunity on product authentication, according to AlpVision.
ASI has teamed up with Chromatan in order to deliver single-use and column-free capture purification services which could save clients 65% in chromatography costs in clinical manufacturing.
Excipient firms that skip lot testing or use alternative analysis methods should justify their decisions according to a new COA guide issued by IPEC Americas.
BASF is moving en masse into omega-3 - especially if its bid for Norwegian player Pronova is approved - but it is technology gained from its May acquisition of a high-dose omega-3 start-up on a remote Scottish island, that is exciting the German giant.
The positive impact drug industry demand for quality is having on the fine chemicals sector was evident at industry trade show CPhI last month according to expert Jan Ramakers.
The proposed changes to European clinical trial regulations accepted by the European Commission (EC) in July will put Europe on an equal playing field, according to Clinipace’s Andrea Schiefer.
Submitting a REMS (Risk Evaluation and Mitigation Strategies) proposal for risky drug developments could earn companies brownie points, according to Quintiles’ Ed Tabor.
Negotiating funding for drugs with local health authorities prior to commercialisation is the key to success for biopharmas working in the changing European market, says Quintiles.
‘CROs: look at the entire portfolio, not just the individual project, when planning clinical studies,’ says DIA’s adaptive design scientific working group.
Sourcing comparator drugs for trials is a complex ‘art’ that requires knowledge of trading, regional regulations and an awareness of drugmakers’ competitive concerns according to Clinigen Group CEO Peter George.
Planning supply chains early is an important part of maintaining margins but is often overlooked by Pharmas too focused on developing the next product in an era of patent expiry says industry consultant.
The European CMO sector is set to double in the next six years and will hit revenues of up to $20.75bn, according to Frost & Sullivan’s Aiswariya Chidambaram.
Pharma companies must become more involved in building patient communities through social media if they want to see a successful trial recruitment process according to Patient Nucleus founder Jamie Blackburn.
Aptar Pharma says its new eDevices can help companies gain quicker regulatory approval for their nasal drug products without having to re-do clinical trials.
Detailed market knowledge and an experienced CMO are still critical to successfully developing a biopharmaceutical or biosimilar according to Cobra Biologics.
Sponsor and CRO perceptions of the quality of outsourced service provision differ markedly according to a study by consulting and survey research organisation, the Avoca Group.
The global contract manufacturing market may be showing signs of recovery but careful investment and focusing on core activities is still the most sensible approach according to Sweden-based CDMO Recipharm.
Taste masking plays a vital role in treatment compliance according to Cargill, which has launched a new flavour technology that it claims can make drugs more pleasant to take and help manufacturers save money.
High potency APIs are becoming a key focus of the pharmaceutical business, with drug makers from all areas racing to establish a foothold in the market.
Endeavour Specialty Chemicals has launched a novel range of pyridinyl thioureas designed to cater for growing pharmaceutical industry interest in the development of prion disease treatments.
Almac says growing demand for non-GMP manufacturing work rather than competition was the key driver for expansion of its product development services business.
Asking the right questions is key to giving pharmaceutical industry contract managers the information they need to select the best CRO partners according to the team behind a new performance assessment project.
